Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 353 followers
Latest posts
Last updated 2 days ago
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised
2 days ago
Group sales grew by 7%1 at constant exchange rates (CER; 2% in...
Reminder: Invitation to Roche’s 3rd Quarter Sales 2025 Presentation
5 days ago
Roche will publish its Sales for the 3rd Quarter of 2025 prior...
Reminder: Invitation to Roche’s 3rd Quarter Sales 2025 Presentation
5 days ago
Roche will publish its Sales for the 3rd Quarter of 2025 prior...
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
5 days ago
Tecentriq reduced the risk of death by 41% and the risk of...
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
5 days ago
FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as...
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
7 days ago
Giredestrant plus everolimus reduced the risk of disease progression or death by...
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
7 days ago
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving...
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis
8 days ago
Positive recommendation based on phase II NOBILITY and phase III REGENCY data...
Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025
9 days ago
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial...
Reminder: Invitation to Roche’s Virtual Ophthalmology Investor Event
11 days ago
We are pleased to invite investors and analysts to participate in our...
Roche’s Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer’s-related amyloid pathology
12 days ago
Rules out Alzheimer’s pathology in early stages to enhance diagnostic pathway efficiencyProvides...
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
12 days ago
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...